Regulatory Considerations for Controlling Intermediates in Type-II Drug Master Files for the Manufacture of Generic Drug Substances

The authors present analysis of the state of control of intermediate identity and quality, based on analysis of recently submitted DMFs.
Mar 15, 2016
Volume 2016 eBook, Issue 1, pg s46-s54

The authors present analysis of the state of control of intermediate identity and quality, based on analysis of recently submitted DMFs.

Read this article from Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.

View other articles in the 2016 Solid Dosage Drug Development and Manufacturing eBook.

native1_300x100
lorem ipsum